Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML

Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gosline, Sara J. C., Tognon, Cristina, Nestor, Michael, Joshi, Sunil, Modak, Rucha, Damnernsawad, Alisa, Posso, Camilo, Moon, Jamie, Hansen, Joshua R., Hutchinson-Bunch, Chelsea, Pino, James C., Gritsenko, Marina A., Weitz, Karl K., Traer, Elie, Tyner, Jeffrey, Druker, Brian, Agarwal, Anupriya, Piehowski, Paul, McDermott, Jason E., Rodland, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327422/
https://www.ncbi.nlm.nih.gov/pubmed/35896960
http://dx.doi.org/10.1186/s12014-022-09367-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327422/
https://www.ncbi.nlm.nih.gov/pubmed/35896960
http://dx.doi.org/10.1186/s12014-022-09367-9

Ejemplares similares